General and administrative expenses also include legal fees relating to patent and corporate matters and professional fees paid for accounting, auditing, consulting and tax services, as well as allocated facilities costs not otherwise included in R&D expenses and other costs such as insurance costs and travel expenses.

filing / Aug 6, 2026 / receipt

The increase of $11.6 million in general and administrative expenses for the three months ended June 30, 2026 was primarily due to an increase in compensation costs of $10.9 million due to increased headcount, including a $6.5 million increase in stock-based compensation, and an increase in other general fees and costs of $2.0 million, partially offset by a decrease in professional and consultant fees of $1.3 million

filing / Aug 6, 2026 / receipt

The increase of $17.6 million in general and administrative expenses for the six months ended June 30, 2026 was primarily due to an increase in compensation costs of $13.6 million due to increased headcount, including a $7.0 million increase in stock-based compensation, an increase in other general fees and costs of $2.7 million, and an increase in professional and consultant fees of $1.2 million, partially offset by

filing / Aug 6, 2026 / receipt

Of the four operating leases that have commenced as of June 30, 2026 , three are leases in which the Company is the lessee for office space.

filing / Aug 6, 2026 / receipt

In the fourth quarter of 2025, the Company entered into an additional non-cancelable operating lease for office space with a term of approximately eight years, which, along with rent payments, is expected to commence in the third quarter of 2026.

filing / Aug 6, 2026 / receipt

General and administrative expenses also include legal fees relating to patent and corporate matters and professional fees paid for accounting, auditing, consulting and tax services, as well as allocated facilities costs not otherwise included in R&D expenses and other costs such as insurance costs and travel expenses.

filing / May 8, 2026 / receipt

The increase of $6.0 million in general and administrative expenses for the three months ended March 31, 2026 was primarily due to an increase in compensation costs of $2.7 million due to increased headcount, including a $0.4 million increase in stock-based compensation, an increase in professional and consultant fees of $2.5 million, and an increase in other general fees and costs of $1.1 million, partially offset b

filing / May 8, 2026 / receipt

due to an increase of $14.5 million in external clinical trial expenses related to higher Chemistry, Manufacturing, and Controls (CMC) costs, as well as an increase of $2.1 million in compensation costs due to increased headcount, including a $0.9 million increase in stock-based compensation, partially offset by a decrease in other research and development costs of $0.3 million.

filing / May 8, 2026 / receipt

Of the four operating leases that have commenced as of March 31, 2026 , three are leases in which the Company is the lessee for office space.

filing / May 8, 2026 / receipt

In the fourth quarter of 2025, the Company entered into an additional non-cancelable operating lease for office space with a term of approximately eight years, which, along with rent payments, is expected to commence in the third quarter of 2026.

filing / May 8, 2026 / receipt